Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;24(6):801-812.
doi: 10.2174/1566524023666230619123752.

High TLX1 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Lung Adenocarcinoma

Liang Zhao  1 , Haiping Zheng  1 , Feng Chen  1 , Huasong Lu  2 , Qian Yu  1 , Xuexin Yan  1 , Xinyu Chen  1 , Qianyu Zhang  1 , Qing Bu  1
Affiliations

High TLX1 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Lung Adenocarcinoma

Liang Zhao et al. Curr Mol Med. 2024.

Abstract

Background: To develop optimal personalized therapy for lung adenocarcinoma (LUAD), potential biomarkers associated with the prognosis are urgently needed. It is unclear what role T Cell Leukemia Homeobox 1 (TLX1) plays in LUAD.

Objective: In this study, TLX1's relationship with LUAD was investigated using TCGA database analysis, bioinformatics analysis, and experimental validation.

Methods: We examined the expression of TLX1 in pan cancer and LUAD, the relationship between TLX1 expression and clinical features, immune infiltration, its diagnostic and prognostic value, as well as TLX1 related pathways. The analysis included various statistical methods, including the Kaplan-Meier method, Cox regression analysis, GSEA, and immune infiltration analysis. TLX1 expression in LUAD cell lines was validated using qRT-PCR.

Result: In LUAD patients, high expression of TLX1 was associated with T stage (P<0.001). High TLX1 expression was associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.18-2.1; P=0.002). And TLX1 HR: 1.619; 95% CI: 1.012-2.590; P=0.044) was independently correlated with OS in LUAD patients. TLX1 expression was associated with the pathways, including Rho GTPase effectors, DNA repair, TCF dependent signaling in response to WNT, signaling by Nuclear Receptors, signaling by Notch, chromatin-modifying enzymes, ESR-mediated signaling, cellular senescence, and transcriptional regulation by Runx1. TLX1 expression was correlated with aDC, Tcm, and TReg cells. The expression of TLX1 was significantly increased in LUAD cells compared to BEAS-2B cells.

Conclusion: An association between high TLX1 expression and poor survival and immune infiltration was found in LUAD patients. There may be a potential role for TLX1 in diagnosis, prognosis, and immunotherapy for LUAD.

Keywords: Lung adenocarcinoma (LUAD); TLX1; biomarker; immune infiltration; prognosis; therapy..

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Arbour K.C.; Riely G.J.; Systemic therapy for locally advanced and metastatic non–small cell lung cancer. JAMA 2019,322(8),764-774 - DOI - PubMed
    1. Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30 - DOI - PubMed
    1. Chen H.; Carrot-Zhang J.; Zhao Y.; Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun 2019,10(1),5472 - DOI - PubMed
    1. Brainard J.; Farver C.; The diagnosis of non-small cell lung cancer in the molecular era. Mod Pathol 2019,32(S1),16-26 - DOI - PubMed
    1. Hirsch F.R.; Scagliotti G.V.; Mulshine J.L.; Lung cancer: Current therapies and new targeted treatments. Lancet 2017,389(10066),299-311 - DOI - PubMed

MeSH terms